Abstract
Alzheimers disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10% of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.
Keywords: Glycosphingolipids, ganglioside, presenilin, neurotrophin, Trk, lipid rafts, cholesterol, familial Alzheimer's disease
CNS & Neurological Disorders - Drug Targets
Title: Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
Volume: 5 Issue: 4
Author(s): Tatsuro Mutoh, Yoshio Hirabayashi, Takateru Mihara, Madoka Ueda, Hiroshi Koga, Akihiro Ueda, Takako Kokura and Hiroko Yamamoto
Affiliation:
Keywords: Glycosphingolipids, ganglioside, presenilin, neurotrophin, Trk, lipid rafts, cholesterol, familial Alzheimer's disease
Abstract: Alzheimers disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10% of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.
Export Options
About this article
Cite this article as:
Mutoh Tatsuro, Hirabayashi Yoshio, Mihara Takateru, Ueda Madoka, Koga Hiroshi, Ueda Akihiro, Kokura Takako and Yamamoto Hiroko, Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2006; 5 (4) . https://dx.doi.org/10.2174/187152706777950710
DOI https://dx.doi.org/10.2174/187152706777950710 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bridge Between Neuroimmunity and Traumatic Brain Injury
Current Pharmaceutical Design Meet Our Associate Editor
Current Molecular Medicine Antitumoral Alkylphospholipids Alter Cell Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Emerging and Alternative Therapies For Parkinson Disease: An Updated Review
Current Pharmaceutical Design Cell Transplantation: A Future Therapy for Narcolepsy?
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Neuroinflammation a Common Link in Neurodegenerative Neurological and Psychiatric Disorders)
Current Pharmaceutical Design Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research The Antioxidants and Pro-Antioxidants Network: An Overview
Current Pharmaceutical Design Aging as an Epigenetic Phenomenon
Current Genomics Dimerization and Ion Binding Properties of S100P Protein
Protein & Peptide Letters Clearing the Brains Cobwebs: The Role of Autophagy in Neuroprotection
Current Neuropharmacology Reacting to Stress: Radical Cellular Pathways for Novel Drug Development
Current Neurovascular Research Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets 2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activity
Current Medicinal Chemistry Cell Based-Gene Delivery Approaches for the Treatment of Spinal Cord Injury and Neurodegenerative Disorders
Current Stem Cell Research & Therapy Expression Analysis of 4-Hydroxynonenal Modified Proteins in Schizophrenia Brain; Relevance to Involvement in Redox Dysregulation
Current Proteomics Regulatory Triangle of Neurodegeneration, Adult Neurogenesis and MicroRNAs
CNS & Neurological Disorders - Drug Targets Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery